PARLIAMENTARY WRITTEN QUESTION
(21 October 2025)

To ask the Secretary of State for Health and Social Care, how many of the commercial arrangements made by NHS England with marketing authorisation holders between January 2020 and September 2025 involving indication-specific pricing were for indications for (a) rare non-oncology and (b) ultra-rare non-oncology conditions.

Asked by:
John Milne (Liberal Democrat)

Between January 2020 and September 2025, NHS England entered into 75 commercial arrangements involving indication-specific pricing. Of these, eight of the commercial agreements have involved indication-specific pricing for rare non-oncology conditions, and of those eight, two were for indications classed as ultra-rare non-oncology conditions.

Please note that the following definitions of rare and ultra rare non-oncology conditions have been applied: rare, meaning a condition which affects less than 1 in 2,000 people, as per the National Health Service rare diseases framework; and ultra-rare, meaning a condition affecting 1 in 50,000 people or fewer in England.

Answered by:
()